545 related articles for article (PubMed ID: 29563491)
1. RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia.
Cheng JX; Chen L; Li Y; Cloe A; Yue M; Wei J; Watanabe KA; Shammo JM; Anastasi J; Shen QJ; Larson RA; He C; Le Beau MM; Vardiman JW
Nat Commun; 2018 Mar; 9(1):1163. PubMed ID: 29563491
[TBL] [Abstract][Full Text] [Related]
2. 5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.
Curik N; Burda P; Vargova K; Pospisil V; Belickova M; Vlckova P; Savvulidi F; Necas E; Hajkova H; Haskovec C; Cermak J; Krivjanska M; Trneny M; Laslo P; Jonasova A; Stopka T
Leukemia; 2012 Aug; 26(8):1804-11. PubMed ID: 22343522
[TBL] [Abstract][Full Text] [Related]
3. Using PU.1 and Jun dimerization protein 2 transcription factor expression in myelodysplastic syndromes to predict treatment response and leukaemia transformation.
Boasman K; Simmonds MJ; Graham C; Saunthararajah Y; Rinaldi CR
Ann Hematol; 2019 Jun; 98(6):1529-1531. PubMed ID: 30721335
[No Abstract] [Full Text] [Related]
4. High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Han X; Medeiros LJ; Zhang YH; You MJ; Andreeff M; Konopleva M; Bueso-Ramos CE
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S30-8. PubMed ID: 27155969
[TBL] [Abstract][Full Text] [Related]
5. GATA-1 Inhibits PU.1 Gene via DNA and Histone H3K9 Methylation of Its Distal Enhancer in Erythroleukemia.
Burda P; Vargova J; Curik N; Salek C; Papadopoulos GL; Strouboulis J; Stopka T
PLoS One; 2016; 11(3):e0152234. PubMed ID: 27010793
[TBL] [Abstract][Full Text] [Related]
6. Forced FOG1 expression in erythroleukemia cells: Induction of erythroid genes and repression of myelo-lymphoid transcription factor PU.1.
Fujiwara T; Sasaki K; Saito K; Hatta S; Ichikawa S; Kobayashi M; Okitsu Y; Fukuhara N; Onishi Y; Harigae H
Biochem Biophys Res Commun; 2017 Apr; 485(2):380-387. PubMed ID: 28216155
[TBL] [Abstract][Full Text] [Related]
7. Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in
Tobiasson M; Pandzic T; Cavelier L; Sander B; Wahlin BE
Leuk Lymphoma; 2019 Dec; 60(13):3316-3319. PubMed ID: 31204875
[No Abstract] [Full Text] [Related]
8. An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia.
Solly F; Koering C; Mohamed AM; Maucort-Boulch D; Robert G; Auberger P; Flandrin-Gresta P; Adès L; Fenaux P; Kosmider O; Tavernier-Tardy E; Cornillon J; Guyotat D; Campos L; Mortreux F; Wattel E
Clin Cancer Res; 2017 Jun; 23(12):3025-3034. PubMed ID: 27881579
[No Abstract] [Full Text] [Related]
9. Up-regulation of SPINT2/HAI-2 by Azacytidine in bone marrow mesenchymal stromal cells affects leukemic stem cell survival and adhesion.
Roversi FM; Cury NM; Lopes MR; Ferro KP; Machado-Neto JA; Alvarez MC; Dos Santos GP; Giardini Rosa R; Longhini AL; Duarte ADSS; Pericole FV; Favaro P; Yunes JA; Saad STO
J Cell Mol Med; 2019 Feb; 23(2):1562-1571. PubMed ID: 30484958
[TBL] [Abstract][Full Text] [Related]
10. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
11. C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation.
Liu D; Zhang XX; Li MC; Cao CH; Wan DY; Xi BX; Tan JH; Wang J; Yang ZY; Feng XX; Ye F; Chen G; Wu P; Xi L; Wang H; Zhou JF; Feng ZH; Ma D; Gao QL
Nat Commun; 2018 Apr; 9(1):1739. PubMed ID: 29712898
[TBL] [Abstract][Full Text] [Related]
12. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.
Ørskov AD; Treppendahl MB; Skovbo A; Holm MS; Friis LS; Hokland M; Grønbæk K
Oncotarget; 2015 Apr; 6(11):9612-26. PubMed ID: 25823822
[TBL] [Abstract][Full Text] [Related]
13. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
Zuber J; Shi J; Wang E; Rappaport AR; Herrmann H; Sison EA; Magoon D; Qi J; Blatt K; Wunderlich M; Taylor MJ; Johns C; Chicas A; Mulloy JC; Kogan SC; Brown P; Valent P; Bradner JE; Lowe SW; Vakoc CR
Nature; 2011 Aug; 478(7370):524-8. PubMed ID: 21814200
[TBL] [Abstract][Full Text] [Related]
14. Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.
Al-Jamal HA; Mat Jusoh SA; Hassan R; Johan MF
BMC Cancer; 2015 Nov; 15():869. PubMed ID: 26547689
[TBL] [Abstract][Full Text] [Related]
15. PU.1 target genes undergo Tet2-coupled demethylation and DNMT3b-mediated methylation in monocyte-to-osteoclast differentiation.
de la Rica L; Rodríguez-Ubreva J; García M; Islam AB; Urquiza JM; Hernando H; Christensen J; Helin K; Gómez-Vaquero C; Ballestar E
Genome Biol; 2013; 14(9):R99. PubMed ID: 24028770
[TBL] [Abstract][Full Text] [Related]
16. HOTAIR suppresses PTEN via DNMT3b and confers drug resistance in acute myeloid leukemia.
Zhou W; Xu S; Chen X; Wang C
Hematology; 2021 Dec; 26(1):170-178. PubMed ID: 33538241
[TBL] [Abstract][Full Text] [Related]
17. Critical Roles for PU.1, GATA1, and GATA2 in the expression of human FcεRI on mast cells: PU.1 and GATA1 transactivate FCER1A, and GATA2 transactivates FCER1A and MS4A2.
Inage E; Kasakura K; Yashiro T; Suzuki R; Baba Y; Nakano N; Hara M; Tanabe A; Oboki K; Matsumoto K; Saito H; Niyonsaba F; Ohtsuka Y; Ogawa H; Okumura K; Shimizu T; Nishiyama C
J Immunol; 2014 Apr; 192(8):3936-46. PubMed ID: 24639354
[TBL] [Abstract][Full Text] [Related]
18. Clinical development of demethylating agents in hematology.
Navada SC; Steinmann J; Lübbert M; Silverman LR
J Clin Invest; 2014 Jan; 124(1):40-6. PubMed ID: 24382388
[TBL] [Abstract][Full Text] [Related]
19. DNA methyltransferases as targets for cancer therapy.
Ghoshal K; Bai S
Drugs Today (Barc); 2007 Jun; 43(6):395-422. PubMed ID: 17612710
[TBL] [Abstract][Full Text] [Related]
20. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
Lowder JN; Taverna P; Issa JP
Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
[No Abstract] [Full Text] [Related]
[Next] [New Search]
